Catalent Expands Biologics Analytical Capabilities with New Laboratories at Center of Excellence in Kansas City, Missouri Read more
Telesis Bio and Cellibre Announce Collaboration to Optimize Development of Future BioXp DBC instrument Read more
PIC Therapeutics Completes $35 Million Series A Financing to Develop Treatments for Drug-Resistant Breast Cancer Read more
Charles River and Nanoscope Therapeutics Announce Multifaceted Gene Therapy Manufacturing Partnership Read more
Syncromune Enters into an Exclusive Worldwide License Agreement with Eucure Biopharma Co., Ltd., to Develop and Commercialize YH002 (OX40 Antibody) and Two Undisclosed Active Ingredients as Components of the Syncrovax Immunotherapy Platform Read more